Oral Shigellosis Vaccine

This application claims a Salmonella typhi Ty21a construct comprising a Shigella sonnei O-antigen biosynthetic gene region inserted into the Salmonella typhi Ty21a chromosome, where heterologous Shigella sonnei form 1 O-antigen is stably expressed together with homologous Salmonella typhi O-antigen. The constructs of this invention elicit immune protection against virulent Shigella sonnei challenge, as well as Salmonella Typhi challenge. Also claimed in this application are methods of recombineering a large antigenic gene region into a bacterial chromosome.

Bacillary dysentery and enteric fevers continue to be important causes of morbidity in both developed and developing nations. Shigella cause greater than one hundred and fifty million cases of dysentery and enteric fever occurs in greater than twenty-seven million people annually. Currently, there is no licensed vaccine to prevent the occurrence of shigellosis. Increasing multiple resistance in Shigella commonly thwarts local therapies.

Potential Commercial Applications: Competitive Advantages:
  • One component of a multivalent Shigellosis vaccine under development
  • Research tool
  • Low cost production
  • Lower cost vaccine
  • Oral vaccine – no needles required
  • Temperature-stable manufacturing process - avoids need for refrigeration during vaccine distribution

Madushini Dharmasena (FDA)
Dennis Kopecko (FDA)

Intellectual Property:
US Application No. 61/701,939
PCT Application No. PCT/US2013/059980

Licensing Contact:
Peter Soukas , J.D.
NIH Office of Technology Transfer
Email: soukasp@mail.nih.gov
Phone: 301-435-4646

OTT Reference No: E-168-2012/0

Updated: Nov-24-2014